The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

Registration Details

  • In-Person Registration: $95.00 (USD)
  • In-Person Registration ends: Friday, March 24, 2023
  • In-Person Fellows: $25.00 (USD)
  • In-Person Fellows ends: Friday, March 24, 2023

Faculty

Meredith E. Clement, MD
Louisiana State University Health Sciences Center
Joseph J. Eron, Jr, MD
University of North Carolina at Chapel Hill
Jeffrey L. Lennox, MD
Emory University School of Medicine
Michael S. Saag, MD
University of Alabama at Birmingham
Hyman Scott, MD, MPH
University of California San Francisco
Sandra A. Springer, MD
Yale University
Tiffany Walker, MD
Emory University

March 31, 2023

8:30 AM - 4:00 PM ET

Address

Cobb Galleria Centre - Ballroom
2 Galleria Parkway
Atlanta
Georgia
30339
United States

Agenda

Last Modified: Jan 26, 2023 @ 12:51 PM

Program Description

This live course will be in person at the Cobb Galleria Centre. There will NOT be a simultaneous virtual component for this course, but the on-demand activity will be available a week following the course.

This live course will focus on recent advances in HIV medicine, including updates from CROI 2023, new antiretroviral formulations and strategies, and will feature a case-based panel discussion on antiretroviral therapy.

To help keep everyone safe, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth.

Assessment of Needs

Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and COVID-19. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs
  • Describe mRNA vaccine technology and the prospects for an HIV vaccine
  • Describe our best current understanding of long-COVID
  • Initiate and monitor HIV prevention intervention strategies, including the use of preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection
  • Manage substance use disorders, including opioids, stimulants, and alcohol

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Additional support has been provided by

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.